JW Pharmaceutical Corp
KRX:001060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JW Pharmaceutical Corp
Intangible Assets
JW Pharmaceutical Corp
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JW Pharmaceutical Corp
KRX:001060
|
Intangible Assets
₩68.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
31%
|
CAGR 10-Years
9%
|
|
|
Yuhan Corp
KRX:000100
|
Intangible Assets
₩184.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
26%
|
CAGR 10-Years
32%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Intangible Assets
₩49.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Intangible Assets
₩113.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Intangible Assets
₩123.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
34%
|
CAGR 10-Years
41%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Intangible Assets
₩5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
JW Pharmaceutical Corp
Glance View
JW PHARMACEUTICAL Corp. engages in the development, manufacture, and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The firm also researches and develops anticancer drugs.
See Also
What is JW Pharmaceutical Corp's Intangible Assets?
Intangible Assets
68.3B
KRW
Based on the financial report for Dec 31, 2025, JW Pharmaceutical Corp's Intangible Assets amounts to 68.3B KRW.
What is JW Pharmaceutical Corp's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
9%
Over the last year, the Intangible Assets growth was 52%. The average annual Intangible Assets growth rates for JW Pharmaceutical Corp have been 61% over the past three years , 31% over the past five years , and 9% over the past ten years .
